Compare Cronos Group Inc (CRON) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.85 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 14.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| CRON | USIG | |
|---|---|---|
Market Cap | $1.18B | $17.53B |
Volume | 968,037 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $3.55 | $52.69 |
52-Week Low | $2.30 | $48.54 |
Typical Hold Time | 22 Days | 44 Days |
Enterprise Value | $387.62M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 and support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9%.
The outlook remains cautious due to bearish technical signals and lack of fundamental data. Investment opportunities include potential support at $48 and institutional accumulation. Key risks involve market volatility and absence of current financial metrics. Investors should await updated earnings reports for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
